trending Market Intelligence /marketintelligence/en/news-insights/trending/Y3ockYrycMI-1W2IoV8Ofg2 content esgSubNav
In This List

Alcon's lens implant for cataract surgery patients gets US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alcon's lens implant for cataract surgery patients gets US FDA approval

Alcon Inc. said the U.S. Food and Drug Administration approved its trifocal intraocular lens for patients undergoing cataract surgery.

A cataract is a cloudy area in the natural lens of a patient's eye that affects vision. Alcon's product, called AcrySof IQ PanOptix, is implanted in a patient's eye to allow clear vision after the removal of the cataract.

The approval is based on a study in 12 investigational sites in the U.S., the former Novartis AG unit said in a news release.

Over four million cataract surgeries are performed in the U.S. annually — a number that is expected to rise by more than 16% by the end of 2024.

Alcon said it expects to begin U.S. surgeon training and patient awareness efforts regarding the product to begin immediately and to ramp up into early 2020.

PanOptix is already being used to correct another eye disorder, presbyopia, in over 70 countries. Presbyopia is a common, age-related condition in which people have trouble focusing their vision on close objects.

Novartis completed the spinoff of Alcon, its eye care business, in April. Alcon shares started trading April 9 on the SIX Swiss Exchange and the New York Stock Exchange.